MIRM MIRUM PHARMACEUTICALS INC US FDA Inspections 8-K Filing 2023 - FDA Review Extension Mirum Pharmaceuticals announced that the FDA has extended the review of the sNDA for LIVMARLI, with the new PDUFA date set for March 13, 2024.Get access to all SEC 8-K filings of the MIRUM PHARMACEUTICALS INC